Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APRIL CATION Docket Number (Optional)

CNTATION	REJECTION OVER A PENDING "REFERENCE" APPLICATION	421842000400
	In re Application of: Harrihar A. PERSHADSINGH	
	Application No.: 10/627,372	
	Filed: July 24, 2003	
	For: NOVEL PPAR LIGANDS THAT DO NOT CAUSE FLUID RETENTION, EDEMA OR CONGESTIVE HEART FAILURE	
	The owner*, Bethesda Pharmaceuticals, Inc. percent interest in the instant application hereby disclaims, except as provided below, the any patent granted on the instant application which would extend beyond the expiration of patent granted on pending reference Application Number 10/801,437, filed of as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted be shortened by any terminal disclaimer filed prior to the grant of any patent on the pend hereby agrees that any patent so granted on the instant application shall be enforceable and the patent granted on the reference application are commonly owned. This agrees the instant application and is binding upon the grantee, its successors or assigns.	date of the full statutory term of any March 15, 2004. ed on said reference application may ing reference application. The owner only for and during such period that it
	In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	
	Check either box 1 or 2 below, if appropriate.	
	1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
	I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
	2. X The undersigned is an attorney or agent of record. Reg. No.	3,318
		3,310
	Signature Signature	November 28, 2005
	Signature	Date
	Shantanu Basu	
	Typed or printed name	(000) 040 5005
		(650) 813-5995 Telephone Number
	X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	
12/01/2005 DTESSE	1 00000006 031952 10627372	
02 FC:2814	65.00 DA	

pa-1026952